Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Biological relevance of Granzymes A and K during E. coli sepsis

  • Uranga-Murillo I.
  • Tapia E.
  • Garzón-Tituaña M.
  • Ramirez-Labrada A.
  • Santiago L.
  • Pesini C.
  • Esteban P.
  • Roig F.J.
  • Galvez E.M.
  • Bird P.I.
  • Pardo Jimeno, J.
  • Arias M.
Aims: Recent in vitro findings suggest that the serine protease Granzyme K (GzmK) may act as a proinflammatory mediator. However, its role in sepsis is unknown. Here we aim to understand the role of GzmK in a mouse model of bacterial sepsis and compare it to the biological relevance of Granzyme A (GzmA). Methods: Sepsis was induced in WT, GzmA-/- and GzmK-/- mice by an intraperitoneal injection of 2x108 CFU from E. coli. Mouse survival was monitored during 5 days. Levels of IL-1a, IL-1ß, TNFa and IL-6 in plasma were measured and bacterial load in blood, liver and spleen was analyzed. Finally, profile of cellular expression of GzmA and GzmK was analyzed by FACS. Results: GzmA and GzmK are not involved in the control of bacterial infection. However, GzmA and GzmK deficient mice showed a lower sepsis score in comparison with WT mice, although only GzmA deficient mice exhibited increased survival. GzmA deficient mice also showed reduced expression of some proinflammatory cytokines like IL1-a, IL-ß and IL-6. A similar result was found when extracellular GzmA was therapeutically inhibited in WT mice using serpinb6b, which improved survival and reduced IL-6 expression. Mechanistically, active extracellular GzmA induces the production of IL-6 in macrophages by a mechanism dependent on TLR4 and MyD88. Conclusions: These results suggest that although both proteases contribute to the clinical signs of E. coli-induced sepsis, inhibition of GzmA is sufficient to reduce inflammation and improve survival irrespectively of the presence of other inflammatory granzymes, like GzmK.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison

  • de Miguel D.
  • Ramirez-Labrada A.
  • Uranga I.
  • Hidalgo S.
  • Santiago L.
  • Galvez E.M.
  • Arias M.
  • Pardo J.
Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low-inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFß and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona
  • Suárez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Pérez, Lorena
  • Bhattarai, Bishan
  • Alari-Pahissa, Elisenda
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc
  • Juan, Manel
  • Pardo, Julián
  • Celià-Terrassa, Toni
  • Rovira, Ana
  • Möker, Nina
  • Zhang, Congcong
  • Colonna, Marco
  • Spanholtz, Jan
  • Malmberg, Karl-Johan
  • Montagut, Clara
  • Albanell, Joan
  • Güell, Marc
  • López-Botet
  • Muntasell, Aura
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4

  • Betrancourt, Alexis
  • Cinko, M. Talha
  • Varanda, Ana Beatriz
  • Arias, Maykel
  • Uranga-Murillo, Iratxe
  • Peña, Natacha
  • Kaps, Lucia-Maria
  • Chau, Long Fung
  • Buratti, Bianca
  • Brägelmann, Johannes
  • de Miguel, Diego
  • Becker, Kerstin
  • Casper, Ramona
  • Martin, Rocio
  • Alcami, Antonio
  • Ferguson, Brian J.
  • Pardo, Julian
  • Rieser, Eva
  • Walczak, Henning
Pattern recognition receptor (PRR)-induced interferon (IFN) is critical for effective immunity. The PRRs Toll-like receptor (TLR) 3, TLR4 and cyclic GMP–AMP synthase (cGAS), together with the stimulator of IFN genes (STING), signal through TANK-binding kinase 1 (TBK1), which activates the type-I/III IFN-inducing transcription factor interferon-response factor 3 (IRF3). The mechanism by which these PRRs activate TBK1 remains unresolved. Here we show that lysine-11 (K11)-linked ubiquitination drives TBK1 activation by these PRRs. The E3 ligase ANKIB1 attaches K11-linked ubiquitin chains to components of the TLR3- and cGAS–STING-induced signalosomes. This facilitates Optineurin recruitment to these complexes, in turn enabling recruitment and activation of TBK1 and IRF3, defining an uncharacterized signalling axis. In mice, ANKIB1 deficiency dampens IFN induction via TLR3 and cGAS–STING, reducing interferonopathy and compromising protection against HSV-1, respectively. Together, our results demonstrate an unanticipated and critical role for ANKIB1-generated K11-linked ubiquitination in the immune response activated by cGAS–STING, TLR3 and TLR4.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sainz, Cristina
  • Andueza, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • de Andrea, Carlos
  • Domínguez, Paulo Pérez
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández-Irigoyen, Joaquín
  • Santamaría, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer.